Related Experiment Video
Updated: Jan 16, 2026

Author Spotlight: Utilizing Next-Generation Polymerized Human Hemoglobin for Improved Donor Lung Evaluation and Preservation in Rats
Published on: June 14, 2024
Clinical and hemodynamic outcomes of hemoperfusion therapy for COVID-19 patients: a historical cohort study
Leila Azizkhani1, Mohammad Ali Yadgary2, Soheila Rabie Siahkali3
1MSc of Nursing, Department of Nursing, School of Nursing and Midwifery, Zanjan University of Medical Sciences, Zanjan, Iran.
Insights
Hemoperfusion may improve clinical and hemodynamic status in severe COVID-19 patients. Further research is needed to confirm these findings for COVID-19 treatment.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Cardiovascular Medicine
Background:
- Inflammation significantly worsens COVID-19 outcomes.
- Hemoperfusion is a technique to remove circulatory toxins and inflammatory mediators.
- The efficacy of hemoperfusion in managing COVID-19 remains unclear.
Purpose of the Study:
- To investigate the clinical and hemodynamic effects of hemoperfusion in COVID-19 patients.
- To assess the impact of hemoperfusion on patient outcomes and physiological parameters.
Main Methods:
- A historical cohort study involving 320 COVID-19 patients in Zanjan, Iran (March 2020-June 2022).
- Data extracted from hospital records using a checklist.
- Statistical analysis included chi-square, Fisher's exact, Mann-Whitney tests, and repeated measure ANOVA using SPSS v.26.
Main Results:
- Hemoperfusion showed a statistically significant association with improved clinical status, reduced lung involvement, and lower intubation rates (P<0.05).
- Significant differences were observed between groups in Glasgow Coma Scale (GCS), platelet count, white blood cell (WBC) count, hemoglobin, respiratory rate, systolic blood pressure, neutrophil and lymphocyte counts, and oxygen saturation (SpO2) over time (P<0.05).
Conclusions:
- Hemoperfusion may lead to improvements in clinical and hemodynamic status for severe COVID-19 patients.
- Additional research is recommended to validate these preliminary findings and establish hemoperfusion's role in COVID-19 management.
Background:
Inflammation exacerbates COVID-19. Hemoperfusion removes toxins and inflammatory elements from the circulation; however, its effect on COVID-19 is uncertain. The clinical and hemodynamic outcomes of COVID-19 patients after hemoperfusion are the focus of this study.
Methods:
This historical cohort study was conducted on a group of 320 individuals diagnosed with COVID-19 between March 2020 and June 2022 in Zanjan, Iran. The required variables were extracted from the patient's hospital records using a pre-established checklist. The chi-square test, Fisher's exact test, the Mann-Whitney test, and the repeated measure ANOVA test were employed. The data analysis programme employed was SPSS version 26.
Results:
Participants in the study had a mean age of 64.82 ± 12.46 years. The association between exposure to hemoperfusion and clinical status, degree of lung involvement, and intubation was found to be statistically significant (P-value < 0.05). There were statistically significant differences between the two groups in the mean GCS, platelet count, WBC, hemoglobin level, breaths per minute, systolic blood pressure, the number of neutrophils and lymphocytes and SPO2 at different time points (P-value group*time < 0.05).
Conclusion:
Patients with severe COVID-19 who undergo hemoperfusion treatment appear to experience improvements in both their clinical and hemodynamic status. We need to conduct additional research in order to verify this.
Related Concept Videos
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Hemodialysis II: Procedure and Complications

